Skip to content
Catalyst

PapersPMID:39044170

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.

The journal of headache and pain2024The record ↗

  1. Finding, moderate evidenceraisesWithdrawal due to adverse events

What moved

1 findingHow to read these marks →
  • “We found high certainty evidence that propranolol increases the proportion of patients who discontinue due to adverse events compared to placebo with a risk difference of 0.02 (95% CI 0.00 to 0.03); absolute risk difference: 20 more per 1,000 (95% CI 0 to 30).”
    Study
    meta-analysis
    Participants
    1,291
    Population
    Adults with migraine; meta-analysis of 20 randomized trials of oral propranolol versus placebo for migraine prophylaxis

Study record

Design
meta-analysis
Species
human
Population
Adults with migraine, enrolled in randomized trials of oral propranolol versus placebo for migraine prophylaxis
Participants
1,291
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
3